PMV Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(70,496) | $(59,705) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,539 | 4,559 |
| Change in fair value of warrant liability | 12,781 | — |
| Offering costs allocated to warrant liability | 2,344 | — |
| Depreciation | 81 | 100 |
| Accretion of discounts on marketable securities | (1,200) | (2,258) |
| Non-cash lease income | (8) | (7) |
| Loss on sales and disposals of fixed assets, net | 24 | 37 |
| Gain on lease termination | (24) | — |
| Other, net | 4 | (15) |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other assets | (24) | 3,005 |
| Accounts payable | (1,517) | (3,180) |
| Accrued expenses | 1,056 | 1,076 |
| Net cash used in operating activities | (52,440) | (56,388) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | — | (14) |
| Proceeds from sale of property and equipment | 1 | 31 |
| Purchases of marketable securities | (78,568) | (67,162) |
| Maturities of marketable securities | 65,966 | 118,873 |
| Net cash (used) provided by investing activities | (12,601) | 51,728 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, Pre-Funded Warrants and Common Stock Warrants | 50,765 | — |
| Offering costs | (3,860) | — |
| Proceeds from the exercise of stock options and common stock issued under the 2020 EIP | 143 | 113 |
| Net cash provided by financing activities | 47,048 | 113 |
| Impact of exchange rates on cash and cash equivalents | 4 | 8 |
| Net decrease in cash and cash equivalents | (17,989) | (4,539) |
| Cash and cash equivalents | ||
| Cash and cash equivalents - beginning of period | 37,983 | 40,876 |
| Cash and cash equivalents - end of period | $19,994 | $36,337 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.